Jessica Fye

“On that outlook for at least $500 million of operating cash flow this year, I think you gave that in the beginning of the year prior to the PRV sale. And I was just wondering if you're able to kind of update your cash flow expectations for the year.”

“For the increase to Brinsupri's peak potential, can you expand a bit on what underpins that? Anything you can add around the earlier and more consistent diagnosis that you're seeing?”

“So I think as we get a little bit more information on the status of our regulatory filings and the timing of when we could see approval and just kind of continue doing kind of our work on the commercial side to our directory we'll have more information to share operator next question your next question comes the line…”

“Maybe for Reshma, I'm curious if you expect to see material differentiation on EGFR across the new IGAN products like Povee and its competitors. And if so, over what time horizon do you think any differentiation on that endpoint would become apparent?”

“Question for Pushkal, recognizing that this is hypothetical, can you elaborate on some of those potential changes available to you with Triton-CM to maximize its probability of success?”